Mednet is now part of the Launchit Ventures Group. Learn more >

Hematology

The following list of reports reflects the latest in findings and outcomes in medical research as presented at major medical meetings and published peer-reviewed medical journals. In this section you can view reports from important congresses as well as summaries of some recently published journal articles. Please let us know if you have a particular area of interest you would like to see covered.

PRIORITY PRESS - Kidney Week 2022 – American Society of Nephrology (ASN)

Updates on aHUS: Latest Insights into Triggers, Diagnosis, and Management Outcomes

In-person/virtual, Orlando, Florida / November 3–6, 2022

In-person/Virtual – Atypical hemolytic uremic syndrome (aHUS) is a form of thrombotic microangiopathy (TMA) that primarily affects the kidney but has a wide variability in its triggers and clinical presentation. In spite of its...

PRIORITY PRESS - EHA2022 Hybrid – European Hematology Association (EHA)

20 Years of Complement Inhibition in PNH: Lessons from the Past, Hope for the Future

In-person/virtual, Vienna, Austria / June 9–12, 2022

In-person/Virtual – Although paroxysmal nocturnal hemoglobinuria (PNH) is a rare and often under-appreciated disease, this year’s EHA hybrid meeting featured a diverse range of presentations on the topic. Two satellite symposia...

PRIORITY PRESS - 63rd Annual Meeting of the American Society of Hematology (ASH)

PNH in the Pandemic: New Science and New Treatments in the Spotlight at ASH 2021

In-person/virtual, Atlanta, Georgia / December 11–13, 2021

In-person/Virtual – The 63rd ASH Annual Meeting featured a solid scientific line-up on paroxysmal nocturnal hemoglobinuria (PNH), despite the rarity of the disease, with five events and 23 posters. For Canadian PNH specialists, the...

PRIORITY PRESS - Kidney Week 2021 (American Society of Nephrology)

Rare Kidney Disease in the Time of COVID: Update on Atypical Hemolytic Uremic Syndrome (aHUS)

Online / November 4–7, 2021

Online – Despite its rarity, atypical hemolytic uremic syndrome (aHUS) featured prominently in this year’s virtual Kidney Week – including the second reported case worldwide of aHUS due to COVID-19. Presenters explored the...

PRIORITY PRESS - EHA2021 Virtual – European Hematology Association (EHA)

Hematology in a time of COVID: Update on Paroxysmal Nocturnal Hemoglobinuria (PNH)

Online / June 9–17, 2021

Online – This year’s European Hematology Association meeting (EHA2021) covered the new medical realities of hematology during the COVID-19 pandemic. Expert panels discussed the impact of SARS-CoV-2 on clinical decision-making in...

MEDICAL FRONTIERS - Annual Meeting of the American Society of Hematology

A New Era of Chemotherapy-free Treatments Emerges for Chronic Lymphocytic Leukemia

Atlanta, Georgia / December 9-12, 2017

Atlanta - The recent approvals of many effective, well-tolerated novel agents for chronic lymphocytic leukemia (CLL) have changed the treatment landscape. Researchers are learning how best to sequence and potentially combine novel...

PRIORITY PRESS - 56th Annual Meeting of the American Society of Hematology (ASH)

Selecting Second- and Third-Line TKIs in CML: Offering Tolerability in the Context of Indefinite Disease Control

San Francisco, California / December 6-9, 2014

San Francisco - A focus on the relative long-term safety and tolerability of available tyrosine kinase inhibitors (TKIs) for treatment of chronic myeloid leukemia (CML) has been intensified by the evidence that drugs in this class, when...

PRIORITY PRESS - 7th Annual Congress of the European Association for Haemophilia and Allied Disorders (EAHAD)

New Treatment Strategies for Prophylaxis in Severe Hemophilia: Moving from Clinical Trials into Real World Practice

Brussels, Belgium / February 26-28, 2014

Brussels - The focus of care in hemophilia A and B has shifted from the management of acute bleeding episodes (on-demand therapy) toward prophylaxis to prevent bleeding episodes and disease sequelae. Currently, hemophilia A patients...

PRIORITY PRESS - 55th Annual Meeting of the American Society of Hematology (ASH)

Strategies for Control of Multiple Myeloma Refined By New and Extended Data Analysis of Major Trials

New Orleans, Louisiana / December 7-10, 2013

New Orleans - Of data with practice-changing implications for control of multiple myeloma presented at ASH 2013, the most significant involved dosing of front-line therapy in those who are transplant-ineligible. In this group, it was shown...

PRIORITY PRESS - XXIV Congress of the International Society on Thrombosis and Haemostasis (ISTH)/ 59th Annual Scientific and Standardization Committee (SSC) Meeting

Potential for Advances in the Treatment of Hemophilia A

Amsterdam, The Netherlands / June 29-July 4, 2013

Amsterdam - Current treatment for patients with hemophilia A, the most common hereditary coagulation disorder, involves intravenous injection of human factor VIII given on demand in response to a bleeding event or as a prophylactic therapy....

PAGE 1 OF 8   1 2 3 4 5 6 7 8
All Rights Reserved - Mednet Inc.
Launchit Ventures
Mednet Inc. is part of the Launchit Ventures Group